CHEPLAPHARM Arzneimittel GmbH

Creditor Relations

Our bonds basically serve to raise long-term funds and thus form a solid financing basis for sustainable positive corporate development.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

Sustainability and Fast Growth

Sustainability and growth are key aspects of our Company’s strategy. This philosophy is also reflected in our diversified financing concept as we strive to be a trustworthy and stable partner for our investors. This is also why our bonds are generally used to raise long-term funds and thus provide a sound financing basis for a long-term positive development of our Company.


Trustful dialog

Financing Strategy

High Yield Bonds
Issuer
CHEPLAPHARM Arzneimittel GmbH
Amount
USD 500,000,000.00
Release
15 October 2020
Maturity
15 January 2028
Ranking
Senior Secured
Coupon
5.500%
Interest payment dates
15 January / 15 July - semi-annually
ISIN
USD1T29ZAB81
WKN
A3H2YN
Governing Law
New York Law
High Yield Bonds
Issuer
CHEPLAPHARM Arzneimittel GmbH
Amount
EUR 500,000,000.00
Release
11 February 2020
Maturity
11 February 2027
Ranking
Senior Secured
Coupon
3.50%
Interest payment dates
15 February / 15 August - semi-annually
ISIN
XS2112973107
WKN
A254SJ
Governing Law
New York Law
High Yield Bonds
Issuer
CHEPLAPHARM Arzneimittel GmbH
Amount
EUR 575,000,000.00
Release
15 October 2020
Maturity
15 January 2028
Ranking
Senior Secured
Coupon
4.375%
Interest payment dates
15 January / 15 July - semi-annually
ISIN
XS2243548273
WKN
A3H2YL
Governing Law
New York Law
Term Loan B
Issuer
CHEPLAPHARM Arzneimittel GmbH
Amount
EUR 980,000,000.00
Release
12 July 2018
Maturity
11 July 2025
Ranking
Senior Secured
Coupon
EURIBOR (0%Floor) +3,50%
Interest periods
one, two, three or six months
Governing Law
English Law
Agent
Deutsche Bank Luxembourg S.A.

Investors Domain

Fields marked with an asterisk (*) are mandatory

Discovering Investor Relations

Investor Relations topics

Back to top expand_less